Paper36600271
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F and 7 others. J Exp Clin Cancer Res, 2023. Cited by 62 papers, by iCite.
Cite this record
ConductScience Library. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. Papers, record 36600271. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36600271
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Immunological | Major topic |
| Drug-Related Side Effects and Adverse Reactions | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Lung Neoplasms | Major topic |
| Female | |
| Humans | |
| Male | |
| Immunotherapy | |
| United States | |
| Adolescent | |
| Young Adult | |
| Adult | |
| Middle Aged | |
| Aged | |
| Aged, 80 and over |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R03 DE028387 | NIDCR NIH HHS | United States | R03DE028387 | PubMed and NIH | NIH RePORTER |
| R01DE028351 | NIDCR NIH HHS | United States | R01DE028351 | PubMed and NIH | NIH RePORTER |
| R03 DE032084 | NIDCR NIH HHS | United States | R03DE032084 | PubMed and NIH | NIH RePORTER |
| R01 DE028351 | NIDCR NIH HHS | United States | R01DE028351 | PubMed and NIH | NIH RePORTER |
| R03DE032084 | NIDCR NIH HHS | United States | R03DE032084 | PubMed and NIH | NIH RePORTER |
References71
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33645548 | Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. | J Clin Invest | 2021 | https://conductscience.org/library/papers/33645548 | PubMed |
| 2 | 32127660 | Trends in clinical development for PD-1/PD-L1 inhibitors. | Nat Rev Drug Discov | 2020 | https://conductscience.org/library/papers/32127660 | PubMed |
| 3 | 28975219 | Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/28975219 | PubMed |
| 4 | 30586539 | The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. | Discov Med | 2018 | https://conductscience.org/library/papers/30586539 | PubMed |
| 5 | 34536948 | Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. | Eur J Cancer | 2021 | https://conductscience.org/library/papers/34536948 | PubMed |
| 6 | 26446948 | Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26446948 | PubMed |
| 7 | 32758477 | Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32758477 | PubMed |
| 8 | 35621637 | Immune Checkpoint Inhibitors in Cancer Therapy. | Curr Oncol | 2022 | https://conductscience.org/library/papers/35621637 | PubMed |
| 9 | 33705549 | Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. | J Natl Cancer Inst | 2021 | https://conductscience.org/library/papers/33705549 | PubMed |
| 10 | 34417437 | Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. | Signal Transduct Target Ther | 2021 | https://conductscience.org/library/papers/34417437 | PubMed |
| 11 | 25918278 | Toxicities of Immunotherapy for the Practitioner. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25918278 | PubMed |
| 12 | 34725502 | Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. | Nat Biotechnol | 2022 | https://conductscience.org/library/papers/34725502 | PubMed |
| 13 | 28817755 | Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/28817755 | PubMed |
| 14 | 31021376 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/31021376 | PubMed |
| 15 | 34761470 | Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. | Hepatol Res | 2022 | https://conductscience.org/library/papers/34761470 | PubMed |
| 16 | 35101302 | Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. | Eur Urol | 2022 | https://conductscience.org/library/papers/35101302 | PubMed |
| 17 | 33764387 | Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/33764387 | PubMed |
| 18 | 33476593 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/33476593 | PubMed |
| 19 | 33317597 | The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. | J Exp Clin Cancer Res | 2020 | https://conductscience.org/library/papers/33317597 | PubMed |
| 20 | 34868071 | Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. | Front Immunol | 2021 | https://conductscience.org/library/papers/34868071 | PubMed |
Cited by44
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 62 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958364 | Immune checkpoints: cross-disease insights and clinical dilemmas. | Biomark Res | 2026 | https://conductscience.org/library/papers/42958364 | PubMed |
| 42913630 | Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade. | Cell | 2026 | https://conductscience.org/library/papers/42913630 | PubMed |
| 42740907 | Avoidance of cardiac toxicity during the application of immune checkpoint inhibitors: a safety systematic review combining network meta-analysis and pharmacovigilance study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42740907 | PubMed |
| 42713225 | Therapeutic mRNA vaccines for lung cancer: reshaping the tumor microenvironment to enhance anti-tumor immunity. | Front Immunol | 2026 | https://conductscience.org/library/papers/42713225 | PubMed |
| 42568649 | The real-world safety profile of enfortumab vedotin with or without pembrolizumab: insights from a comparative analysis of FAERS. | Front Immunol | 2026 | https://conductscience.org/library/papers/42568649 | PubMed |
| 42496605 | Pharmacovigilance Evaluation of Noninfectious Myocarditis and Pericarditis in Immune Checkpoint Inhibitor Recipients Using FAERS. | Technol Cancer Res Treat | 2026 | https://conductscience.org/library/papers/42496605 | PubMed |
| 42495626 | Integrative analysis of FAERS, network toxicology, and Mendelian randomization identifies potential targets in paclitaxel-associated systemic sclerosis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42495626 | PubMed |
| 42370183 | Understanding immune checkpoint inhibitors-related myocarditis: Mechanisms and targeted therapeutic pathways. | Theranostics | 2026 | https://conductscience.org/library/papers/42370183 | PubMed |
| 42256063 | Rational design of a V-shaped DNA-targeted photosensitizer enables endogenous DNA damage-driven cGAS-STING activation and systemic antitumor immunity. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42256063 | PubMed |
| 42212151 | Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42212151 | PubMed |
| 42079638 | Dynamic changes in gut microbiota and metabolites in advanced lung cancer patients with immune-related adverse events. | Front Immunol | 2026 | https://conductscience.org/library/papers/42079638 | PubMed |
| 42043855 | Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors. | Cancer Med | 2026 | https://conductscience.org/library/papers/42043855 | PubMed |
| 41972167 | Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database. | Front Immunol | 2026 | https://conductscience.org/library/papers/41972167 | PubMed |
| 41968610 | Endocrinologist-Led Management of Endocrine Immune-Related Adverse Events: Real-World Evidence Supporting the Japan Endocrine Society Guidelines. | Cancer Med | 2026 | https://conductscience.org/library/papers/41968610 | PubMed |
| 41858812 | Comparative Safety Analysis of Hydromorphone and Morphone Sulfate: Evidence from the 2004-2024 FAERS. | J Pain Res | 2026 | https://conductscience.org/library/papers/41858812 | PubMed |
| 41774718 | Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS. | PLoS One | 2026 | https://conductscience.org/library/papers/41774718 | PubMed |
| 41754815 | Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors: A Scoping Review. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41754815 | PubMed |
| 41629133 | Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41629133 | PubMed |
| 41565210 | Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system. | Eur Heart J Cardiovasc Pharmacother | 2026 | https://conductscience.org/library/papers/41565210 | PubMed |
| 41261920 | Circadian rhythm in immunotherapy and cellular therapy: impacts on the tumor microenvironment. | Acta Biochim Biophys Sin (Shanghai) | 2026 | https://conductscience.org/library/papers/41261920 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ARID1A | 8289 | PubTator's text mining | https://conductscience.org/library/genes/8289 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36600271
GET https://conductscience.org/api/papers/v1/36600271/references?page=2